Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kelch-like protein 13 (KLHL13) is a substrate adaptor protein of the BTB-CUL3-RBX1 (BCR) E3 ubiquitin-protein ligase complex, necessary for proper mitotic progression and cytokinesis[2][3]. KLHL13 facilitates ubiquitination of specific substrate proteins, including Aurora kinase B (AURKB), thereby regulating chromosome segregation during mitosis[2]. This protein contains characteristic domains of the KLHL family: a BTB/POZ domain (protein binding and dimerization), a BACK domain (whose mutations are linked with disease), and five or six Kelch repeat motifs (involved in substrate recognition)[1]. KLHL family proteins play important roles in cellular protein degradation, cytoskeletal organization, and cellular morphology, and have been implicated in both hereditary diseases and cancer[1][4]. Mutations or dysfunction in KLHL13 or related proteins can perturb cell division and have been associated with neurological and oncological disorders such as Charcot-Marie-Tooth Disease and cancer[2]. Key notes: - No drugs are currently listed as direct KLHL13 antagonists/agonists. - KLHL13 is not a classical receptor, ion channel, or enzyme, but rather an E3 ligase complex adaptor, relevant for targeted protein degradation pathways[2][4]. - No known biomarkers or notable toxicity concerns specific to KLHL13 (apart from general disease association if mutated/disrupted). - The family and this gene are well-annotated, with no nomenclature errors.
Functions as an adaptor protein with Cullin 3 for E3 ubiquitin ligase–directed substrate ubiquitination and degradation[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch-like protein 13 (KLHL13).